$SLS Sellas Life Sciences Group Inc. has recently drawn attention as one of the more heavily shorted stocks on Wall Street, with short interest nearing 28% of its shares outstanding. This elevated short interest highlights investor caution and potential volatility, especially given the company's focus in the challenging biotechnology sector. Despite this, Sellas is advancing its pipeline, notably with its selective CDK9 inhibitor, SLS009 (tambiciclib), which is showing promising preclinical results in pancreatic ductal adenocarcinoma (PDAC). The company will present three posters on this research at the upcoming AACR Conference on Pancreatic Cancer later this month, underscoring its commitment to tackling one of the toughest solid tumors through innovative therapeutic approaches.
Meanwhile, $SLS has experienced mixed market reactions tied to its broader oncology efforts. The stock surged earlier this year, fueled by momentum around its AML immunotherapy candidate galinpepimut-S (GPS) and the CDK9 inhibitor SLS009, with shares climbing significantly over the past 12 months. However, recent investor concerns surfaced after reports indicated the phase 3 AML trial reached a critical patient death milestone without immediate disclosure from the company, causing a notable 13% drop in share price. Despite this, institutional interest remains strong, with hedge funds substantially increasing their holdings in the second quarter, signaling confidence in Sellas’ long-term potential amid ongoing clinical developments and possible strategic moves hinted at by new executive severance agreements.
As the market remains closed tonight, investors will be watching closely when U.S. markets reopen Friday morning at 9:30 AM ET, especially with the AACR conference presentations and upcoming trial readouts poised to influence $SLS’s trajectory.
Did you know?
Stocks with high short interest can experience sharp price swings if positive news triggers a short squeeze, forcing short sellers to buy shares and driving prices even higher.
Disclaimer
This content is for entertainment and discussion purposes only. It is based on publicly available headlines and social media commentary, which can be messy and ever-evolving. We are not financial advisors, and this is not investment advice. The publisher may hold positions in securities mentioned. We aim to keep things accurate—if you catch something off, please let us know.
Powered by - Trading Watch Premium
This data is 100% free and is made possible by our Monthly Supporters.
No Comments